Drug Type Bispecific antibody |
Synonyms KM252 |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bile Duct Neoplasms | Preclinical | China | 31 Mar 2021 | |
Bile Duct Neoplasms | Preclinical | China | 31 Mar 2021 | |
Bladder Cancer | Preclinical | China | 31 Mar 2021 | |
Bladder Cancer | Preclinical | China | 31 Mar 2021 | |
Colorectal Cancer | Preclinical | China | 31 Mar 2021 | |
Colorectal Cancer | Preclinical | China | 31 Mar 2021 |